DPAt a glance
Core facts about the doctor and the hospital, as provided by the hospital.
2 areasSpecialties: Head of the Gastrointestinal and Endocrine Cancers Unit, InstitutoOncológico Baselga
OncologyCategory
English, Spanish, CatalanLanguages
JCIAccredited hospital · Madrid
US$940 from5 priced items
35 staffListed at this hospital
Dr. Josep Tabernero is a Hospital Quirónsalud Barcelona. Head of the Gastrointestinal and Endocrine Cancers Unit, Instituto Oncológico Baselga at Grupo Quirónsalud in Madrid, Spain, a JCI-accredited center. Lists Head of the Gastrointestinal and Endocrine Cancers Unit and InstitutoOncológico Baselga. The hospital lists prices from US$940.
About
Medical specialisation: medical oncology.
Area of special training: GI and endocrine tumors.
Membership in International scientific associations:
Area of special training: GI and endocrine tumors.
Membership in International scientific associations:
- ESMO – European Society for Medical Oncology. President elect, 2018-2019.
- ASCO – American Society of Medical Oncology.
- AACR – American Association for Cancer Research.
- ECCO – European Cancer Organization.
- EORTC – European Organization for Research and Treatment of Cancer.
No. of publications in International journals. Over 250 publications in journals, including: the Lancet, the New England Journal of Medicine, the Annals of Oncology, the Journal Clinical Oncology, the Oncologist, Cancer Chemotherapy Pharmacology, Nature, etc. Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer. Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, Van Cutsem E, Guan X, Boedigheimer M, Ang A, Twomey B, Bach BA, Jung AS, Bardelli A. Ann Oncol. 2017 Sep 4. doi: 10.1093/annonc/mdx504 Cancer: A precision approach to tumour treatment. Dienstmann R, Tabernero J. Nature. 2017 Aug 3;548(7665):40-41. doi: 10.1038/nature23101.
He has participated in the clinical trials that led to the development medications, including: panitumumab, cetuximab, aflibercept, regorafenib and ramucirumab. Tas102
He has participated in the clinical trials that led to the development medications, including: panitumumab, cetuximab, aflibercept, regorafenib and ramucirumab. Tas102
Ask the doctor's team about your case
Send your reports and questions to Grupo Quirónsalud. The hospital replies through Health-Tourism.com.
Free consultation • No obligation • Direct communication with the hospital
